Literature DB >> 11432411

Levels of cognitive and linguistic development in Angelman syndrome: a study of 20 children.

W H Andersen1, R K Rasmussen, P Strømme.   

Abstract

Angelman syndrome (AS) is a genetic disorder associated with severe developmental delay. The purpose of this study was to investigate cognitive and linguistic development in AS. Piaget's developmental model was used to evaluate the test results. The participants comprised 20 children (14 boys and 6 girls) aged 2-14 years (median age 7.4 years). AS was diagnosed either according to typical clinical criteria or confirmatory genetic testing. Cognitive functioning was evaluated with Griffiths' Mental Development Scale. Language development was also evaluated with Receptive-Expressive Emergent Language Scale 2 (REEL-2). Cognitive functioning, based on results on the Performance Scale, never exceeded Piaget's sensorimotor stage, 0-2 years. The median mental age for language development was 9 months. Expressive verbal vocabulary consisted of less than 2 words (n = 11), 2-3 words (n = 7) and 4-5 words (n = 2). Analyses according to REEL-2 did not indicate a consistent discrepancy between impressive and expressive language.

Entities:  

Mesh:

Year:  2001        PMID: 11432411

Source DB:  PubMed          Journal:  Logoped Phoniatr Vocol        ISSN: 1401-5439            Impact factor:   1.487


  14 in total

1.  A neurodevelopmental survey of Angelman syndrome with genotype-phenotype correlations.

Authors:  Jennifer K Gentile; Wen-Hann Tan; Lucia T Horowitz; Carlos A Bacino; Steven A Skinner; Rene Barbieri-Welge; Astrid Bauer-Carlin; Arthur L Beaudet; Terry Jo Bichell; Hye-Seung Lee; Trilochan Sahoo; Susan E Waisbren; Lynne M Bird; Sarika U Peters
Journal:  J Dev Behav Pediatr       Date:  2010-09       Impact factor: 2.225

2.  Social-emotional processing in nonverbal individuals with Angelman syndrome: evidence from brain responses to known and novel names.

Authors:  A P Key; D Jones
Journal:  J Intellect Disabil Res       Date:  2018-11-23

3.  Two Angelman families with unusually advanced neurodevelopment carry a start codon variant in the most highly expressed UBE3A isoform.

Authors:  Anjali Sadhwani; Neville E Sanjana; Jennifer M Willen; Stephen N Calculator; Emily D Black; Lora J H Bean; Hong Li; Wen-Hann Tan
Journal:  Am J Med Genet A       Date:  2018-05-07       Impact factor: 2.802

Review 4.  The comorbidity of autism with the genomic disorders of chromosome 15q11.2-q13.

Authors:  Amber Hogart; David Wu; Janine M LaSalle; N Carolyn Schanen
Journal:  Neurobiol Dis       Date:  2008-09-18       Impact factor: 5.996

Review 5.  Angelman syndrome: a review of the clinical and genetic aspects.

Authors:  J Clayton-Smith; L Laan
Journal:  J Med Genet       Date:  2003-02       Impact factor: 6.318

6.  Developmental Skills of Individuals with Angelman Syndrome Assessed Using the Bayley-III.

Authors:  Anjali Sadhwani; Anne Wheeler; Lynne M Bird; Wen-Hann Tan; Angela Gwaltney; Sarika U Peters; Rene L Barbieri-Welge; Lucia T Horowitz; Lisa M Noll; Rachel J Hundley
Journal:  J Autism Dev Disord       Date:  2021-01-30

Review 7.  Angelman syndrome: review of clinical and molecular aspects.

Authors:  Lynne M Bird
Journal:  Appl Clin Genet       Date:  2014-05-16

8.  Neurodevelopmental profile in Angelman syndrome: more than low intelligence quotient.

Authors:  S Micheletti; F Palestra; P Martelli; P Accorsi; J Galli; L Giordano; V Trebeschi; E Fazzi
Journal:  Ital J Pediatr       Date:  2016-10-21       Impact factor: 2.638

Review 9.  Unmet clinical needs and burden in Angelman syndrome: a review of the literature.

Authors:  Anne C Wheeler; Patricia Sacco; Raquel Cabo
Journal:  Orphanet J Rare Dis       Date:  2017-10-16       Impact factor: 4.123

10.  From Cortical and Subcortical Grey Matter Abnormalities to Neurobehavioral Phenotype of Angelman Syndrome: A Voxel-Based Morphometry Study.

Authors:  Gayane Aghakhanyan; Paolo Bonanni; Giovanna Randazzo; Sara Nappi; Federica Tessarotto; Lara De Martin; Francesca Frijia; Daniele De Marchi; Francesco De Masi; Beate Kuppers; Francesco Lombardo; Davide Caramella; Domenico Montanaro
Journal:  PLoS One       Date:  2016-09-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.